5 European Projects Found
Searched on 125080 European Projects
FINISHED
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)
Start date: Jan 1, 2015, End date: Dec 31, 2019,
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Read Project
34
Partners Participants
FINISHED
European Patients' Academy on Therapeutic Innovation (EUPATI)
Start date: Feb 1, 2012, End date: Jan 31, 2017,
"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Read Project
33
Partners Participants
FINISHED
Incorporating real-life clinical data into drug development (GETREAL)
Start date: Oct 1, 2013, End date: Dec 31, 2016,
When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Read Project
32
Partners Participants
FINISHED
Drug Disease Model Resources (DDMORE)
Start date: Mar 1, 2011, End date: Aug 31, 2016,
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project
28
Partners Participants
FINISHED
The Open Pharmacological Concepts Triple Store (OPEN PHACTS)
Start date: Mar 1, 2011, End date: Feb 29, 2016,
Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Read Project
